10 early AI biotech startups, from one post on november 10 2026. Each line below starts with what that post said, then what the company's own site says. The longer article is the X article.
the ten
Nurture Bio (@nurturebio). The post: makes the epigenome readable and remodelable. The site uses the same claim, and adds that the point is to accelerate adaptation.
Permanence Bio (@permanencebio). The post: prevents cancer by stopping mutations before they happen. The site says it is developing drugs that shield DNA from damage, protecting people during radiation exposure and cancer treatment now, and working toward preventing cancer.
Romix Biosciences (@romixbio). The post: one blood draw, a full-body RNA readout of disease. The site calls it a liquid biopsy for deeper insight into disease biology and therapeutic activity, and asks about cell-free RNA.
TychoBio (@tychobio_ai). The post: designs RNA therapeutics with the lab in the loop. The site says it designs RNA therapeutics, and that its data-generation platform unlocks scaling laws for gene therapies.
FinalDose (@finaldoselfg). The post: one programmable drug for all cancers. The site calls it a complete architecture for cancer therapy: DNA gives the address, programmability gives the scale.
five more
Moab Therapeutics (@moabtherapeutic). The post: AI-designed minibinders for its own pipeline. The site says it is advancing a pipeline of potent binders, and that partners can design therapeutics on the same platform.
Ascent Bio (@ascentbio). The post: an AI scientist for drug design, used at 40+ institutions. The site calls the product a semi-autonomous research platform for drug design. The page title is "AI Scientist For Drug Design."
Generative Selection (@genselectai). The post: AI and a wet lab in a closed loop, designing proteins. The site says it builds productive, self-improving scientific intelligence: a scientific reasoning layer with a lab in the loop.
Exin Therapeutics (@exintx). The post: neuroAI for genetic therapies in epilepsy, autism and Parkinson's. The account lists no company site.
Invoke Bio (@invokebio). The post: AI-picked targets for personalized cancer vaccines. The site says its immunogenicity prediction engine identifies tumor targets at 3x the accuracy of industry benchmarks, and that the work is in clinic at Stanford.
A funded biotech pair from earlier in the year is Adaptyv Bio and Keenable. Announced rounds from this stretch are on the fundraise ledger and in startups flagged before they raised. The nearest sector page is AI startups. The november fundraise lists are november 6 and november 13.
Frontrun finds founders and startups first. The AI deal flow agent for venture investors.
follow from the front: frontrun.vc
see the signal this article is built on
frontrun tracks the follow graphs of 2,900+ venture investors and flags companies months before rounds are announced.
start a 7-day free trial →or see trending freeopen source deal flow
companies and founders surfaced on frontrun. curated, every week.